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ttp://dx.doi.org/10.1016/j.ajpath.2013.09.011Methamphetamine is the second most frequently used illicit drug in the United States. Methamphet-
amine abuse is associated with increased risk of HIV-1 acquisition, higher viral loads, and enhanced
HIV-1 pathogenesis. Although a direct link between methamphetamine abuse and HIV-1 pathogenesis
remains to be established in patients, methamphetamine has been shown to increase HIV-1 replication
in macrophages, dendritic cells, and cells of HIV transgenic mice. Intriguingly, the effects of meth-
amphetamine on HIV-1 replication in human CD4þ T cells that serve as the primary targets of infection
in vivo are not clearly understood. Therefore, we examined HIV-1 replication in primary CD4þ T cells in
the presence of methamphetamine in a dose-dependent manner. Our results demonstrate that meth-
amphetamine had a minimal effect on HIV-1 replication at concentrations of 1 to 50 mmol/L. However, at
concentrations >100 mmol/L, it inhibited HIV-1 replication in a dose-dependent manner. We also
discovered that methamphetamine up-regulated the cellular antieHIV-1 microRNAs (miR-125b, miR-
150, and miR-28-5p) in CD4þ T cells. Knockdown experiments illustrated that up-regulation of the
anti-HIV miRNAs inhibited HIV-1 replication. These results are contrary to the paradigm that metham-
phetamine accentuates HIV-1 pathogenesis by increasing HIV-1 replication. Therefore, our ﬁndings
underline the complex interaction between drug use and HIV-1 and necessitate comprehensive under-
standing of the effects of methamphetamine on HIV-1 pathogenesis. (Am J Pathol 2014, 184: 92e100;
http://dx.doi.org/10.1016/j.ajpath.2013.09.011)Supported by National Institute on Drug Abuse/NIH grants DA024558,
DA30896, and DA033892, the Vanderbilt Clinical Translational Science
Award grant UL1RR024975, the Meharry Translational Research Center
Clinical Translational Science Award grant, National Center for Research
Resources/NIH grant U54 RR026140, National Institute on Minority Health
and Health Disparities/NIH grant U54 MD007593, and National Institute on
Drug Abuse/NIH Diversity-Promoting Institutions Drug Abuse Research
Program grant R24DA021471 (C.D.).Substance use is a major barrier for combating the HIV
pandemic because it is associated with increased HIV trans-
mission, increased viral load, and poor adherence to
therapy.1e4 Accumulating evidence also suggests associations
between substance use and HIV disease progression and
AIDS-associated clinical outcomes.5e8 Recreational meth-
amphetamine (METH) use is one of the fastest-growing sub-
stance use problems in the United States.9 METH use
enhances high-risk sexual behaviors and increases the likeli-
hood of HIV-1 acquisition.10 METH is also associated with
higher viral loads, development of antiretroviral resistance,
and rapid progression to AIDS.11e14 However, direct and
molecular effects of METH on HIV-1 infection and disease
progression remain poorly understood. Several mechanisms
have been proposed to support the effects of METH on HIV-1
pathogenesis. METH has been shown to increase HIV-1
replication in dendritic cells (DCs)15 and monocyte-derivedstigative Pathology.
.macrophages.16 Furthermore, METH has been suggested to
activate HIV-1 long-terminal repeat (LTR) promoter-mediated
transcription.17 A study using the JR-CSF/hu-CycT1 mouse
model demonstrated that METH could increase HIV-1 repli-
cation in CD4þ T cells.18 However, the effects of METH on
HIV-1 replication in human CD4þ T cells that are primary
targets of HIV-1 infection and replication in vivo19 remain
largely unclear. Therefore, we evaluated effects of METH on
HIV-1 replication in human primary CD4þ T cells. We
METH Inhibits HIV-1 Replicationpuriﬁed primary CD4þ T cells from the peripheral blood
mononuclear cells (PBMCs) and activated by phytohemag-
glutinin (PHA). The activated CD4þ T cells were then infected
with HIV-1, and replication was monitored with or without
METH. Intriguingly, our results demonstrate that METH in-
hibits HIV-1 replication in CD4þ T cells in a dose-dependent
manner. Our molecular studies suggest that METH inhibits
HIV-1 replication by up-regulating the cellular antieHIV-1
miRNAs. The inhibitory effect ofMETHdescribed herein is in
contrast to the earlier reports describing potentiating effects of
METH on HIV-1 replication. Therefore, it is critical to better
understand the molecular interplay between METH abuse and
HIV-1 pathogenesis.
Materials and Methods
Isolation of PBMCs and CD4þ T Cells
Blood was purchased from the New York Blood Center as per
the Meharry Medical College (Nashville, TN) Institutional
ReviewBoard. PBMCswere isolated by Ficoll-PaquePremium
reagent (GE Healthcare, Pittsburgh, PA), and CD4þ T cells
were isolated by negative selection as per our published pro-
tocol.20 The purity of CD4þ T cells was measured as per a
published method.20 Cells with>95% purity were activated by
5 mg/mL PHA for 48 hours and cultured with 20 U/mL IL-2
(Sigma, St. Louis, MO). SupT1 cells were obtained from
ATCC (Manassas, VA) and maintained in complete RPMI
1640 medium that contains 10% fetal bovine serum and
antibiotics.
Cytotoxicity of METH
Methamphetamine hydrochloride was obtained from Sigma.
We used 1 to 1000 mmol/LMETH to mimic the physiological
concentrations of METH in drug abusers; these concentra-
tions can vary from 10 to 50 mmol/L in blood and from 240 to
1144 mmol/L in spleen and brain.21,22 Cells were treated with
METH for 24 to 48 hours, and cytotoxicity was measured by
MTT assay as per the manufacturer’s instructions (Millipore,
Billerica, MA). Apoptosis was measured by staining cells
with annexin V (AV) and propidium iodide (PI) (Beckman
Coulter, Brea, CA). After treatment, cells were washed,
stained, and analyzed by ﬂow cytometry using FACSCalibur
(Becton Dickinson, San Jose, CA).
Measurement of HIV-1 Replication
Infectious HIV-1 and VSV-G pseudotyped HIV-1 were
produced as per our published protocol.20 A total of 1  106
activated CD4þ T cells were infected with HIV-1 LAI (X4)
and BAL (R5) virions, with or without spinoculation in the
presence of 5 mg/mL polybrene (Sigma), and 4  105 cells/
mL were cultured, with or without METH. Infection was
measured by detecting the intracellular HIV-1 p24 by
ﬂuorescence-activated cell sorter (FACS), as per ourThe American Journal of Pathology - ajp.amjpathol.orgpublished protocol.20 Extracellular p24 was measured in the
supernatants of the infected cells using the HIV-1 p24
antigen-capture ELISA (Frederick, MD), as per supplier
protocol. SupT1 cells were infected with pseudotyped vi-
rions [HIV-1 green ﬂuorescent protein (GFP) or HIV-1
luciferase], and infection was measured by FACS or lucif-
erase activity, as per our published protocol.20 In infection
experiments, METH was added after infection.
miRNA Expression and Knockdown Assays
Total RNA was isolated from cells by an miRNeasy mini kit
(Qiagen, Valencia, CA), and real-time RT-PCR was per-
formed using miRNA-speciﬁc primers (Exiqon, Vedbaek,
Denmark). miRNA expression was normalized to 5s-rRNA
expression. For knockdown assays, inhibitors and negative
controls were purchased from Dharmacon (Lafayette, CO).
Inhibitors or scrambled controls (100 pmol) were transfected
to SupT1 cells using a Neon Transfection System (Life
Technolgies, Carlsbad, CA). Cells were recovered in pre-
warmed antibiotic-free RPMI 1640 medium and incubated for
3 hours at 37C. Then, the cells were infected to determine the
effects of antieHIV-1 miRNAs on HIV-1 replication.
Transcription Assay
HIV-1 LTR-GFP reporter construct (AIDS Research and
Reference Reagent Program, Division of AIDS, National
Institute of Allergy and Infectious Diseases, NIH, Bethesda,
MD) was transfected into SupT1 cells by the Neon Trans-
fection System and into primary CD4þ T cells by Amaxa
Nucleofactor (Lonza, Walkersville, MD) as per manufacturer’s
protocol. The cells were treated withMETH after infection, and
GFP expression was measured by FACS after 24 hours.
Statistical Analysis
Data were analyzed by one-way analysis of variance. Com-
parisons between two groups were conducted using Student’s
t-test. Results were considered signiﬁcant when P < 0.05.
Data are presented as means  SD.
Results
METH Inhibits HIV-1 Replication in CD4þ T Cells
To examine the effects of METH on HIV-1 replication in
CD4þ T cells, ﬁrst we infected the CD4þ T-cell model SupT1
cells with pseudotyped HIV-1 GFP reporter virus and treated
the cells with METH in a dose-dependent manner (1 to 1000
mmol/L). After 48 hours of infection, intracellular GFP was
measured by FACS to monitor single-cycle HIV-1 replication.
METH up to a 50 mmol/L concentration had no impact on GFP
expression, whereas at concentrations >100 mmol/L, METH
reduced GFP expression in a dose-dependent manner
(Supplemental Figure S1A). The maximum inhibitory effect
was observed at 1000 mmol/L of METH with approximately93
Mantri et althreefold decrease in GFP expression (Supplemental
Figure S1B). Then, we infected primary CD4þ T cells with
infectious HIV-1 LAI virions (X4 tropic). After 72 hours of
infection, intracellular and extracellular p24 levels were
measured by FACS and ELISA, respectively. Our data illus-
trated thatMETHup to 50mmol/L had no effect on intracellular
p24 expression (Supplemental Figure S1C). However, intra-
cellular p24 expression decreased in a dose-dependent manner
with 100 to 1000 mmol/L concentrations of METH
(Figure 1A). Notably, a signiﬁcant reduction in intracellular
p24 levels was observed in cells derived from ﬁve of six donors
(Figure 1B). METH also showed a dose-dependent inhibitory
effect on virion release, as measured by the p24 levels in the
supernatants of infected primary CD4þ T cells (Figure 1, C and
D). In both intracellular and extracellular p24 assays, maximum
inhibitory activity was observed with METH at 1000 mmol/L.
Infection at a lower multiplicity of infection and without spi-
noculation also produced similar results (Supplemental
Figure S2), solidifying the inhibitory effects of METH on
HIV-1 replication. An earlier study by Toussi et al18 reported
that METH increased replication of R5 virions in primary
CD4þ T cells. Therefore, we also infected primary CD4þ T
cells with HIV-1 BAL (R5 tropic) virions and measuredFigure 1 METH inhibits HIV-1 replication in primary CD4þ T cells. A: Primary
isolation, the purity of CD4þ T cells was determined by FACS. CD4þ T cells with a p
LAI by spinoculation, and cultured in the presence or absence of METH. Productiv
after infection by FACS. B: Data from six different donors with percentage inhibito
CD4þ T cells. C: Measurement of extracellular p24 levels in the supernatants of inf
released from infected primary CD4þ T cells isolated from three different donors.
Statistical analysis was performed by analysis of variance. *P < 0.05.
94replication with or without METH. Our data showed that
METH also inhibits replication of HIV-1 BAL virions in a
dose-dependent manner (Figure 2, A and B). The low level of
infection of BAL virions is not surprising given that CCR5-
using R5 virions have lower infectivity toward CD4þ T cells
compared with C-X-C receptor (CXCR) 4 using X4 tropic
virions.23 Collectively, these data strongly suggest that METH
inhibits HIV-1 replication in CD4þ T cells.
The Inhibitory Effects of METH Are Not Due to Reduced
Viral Transcription
Because METH has been reported to regulate HIV-1
LTR-driven transcription,17,18 we examined whether METH
targeted HIV-1 transcription. We transfected the HIV-1 LTR-
GFP reporter construct into SupT1 and primary CD4þ T cells
and measured GFP expression by FACS after 24 to 48 hours.
Notably, METH up to 1000 mmol/L concentration showed
minimal/no inhibitory effect on HIV-1 LTR-driven GFP
expression in either SupT1 or primary CD4þ T cells
(Figure 3A). These data suggest that the inhibitory effects of
METH on HIV-1 replication in CD4þ T cells are most likely
not due to decreased viral transcription.CD4þ T cells were isolated by negative selection from human PBMCs. After
urity >95% were activated by PHA for 48 to 72 hours, infected with HIV-1
e infection was measured by detecting intracellular viral p24 protein 3 days
ry activity of METH calculated from intracellular p24 expression in infected
ected primary CD4þ T cells by ELISA assay. D: Percentage inhibition of p24
Results are expressed as means  SD from three independent experiments.
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Figure 2 METH inhibits replication of R5 tropic HIV-1 in CD4þ T cells. A: Activated primary CD4þ T cells were infected with HIV-1 BAL virions by spi-
noculation and cultured in the presence or absence of METH. Productive infection was measured by detecting intracellular viral p24 protein 3 to 4 days after
infection by FACS. B: Data from three different donors with relative inhibition in intracellular p24 expression in the presence of METH. Results are expressed as
means  SD from three independent experiments. Statistical analysis was performed by analysis of variance. *P < 0.05.
METH Inhibits HIV-1 ReplicationCytotoxicity Does Not Contribute to the Inhibitory
Effects of METH on HIV-1 Replication
Given that METH has been shown to induce cytotoxicity to
various cell types, we examined whether cytotoxicity
contributed toward the inhibitory effects of METH. To test
this, an MTT-based cytotoxicity assay was conducted. Our
data indicated that METH up to 1000 mmol/L had minimal
toxicity toward SupT1 and primary CD4þ T cells
(Figure 3B). We also tested METH’s effect on CD4þ T-cell
apoptosis by AV and PI staining to examine METH’s effect
on early apoptosis (AV positive), late apoptosis (PI and AV
positive), and necrosis (PI positive). Notably, METH up to
500 mmol/L minimally altered the percentage of AV (þ),
AV/PI (þ), and PI (þ) SupT1 cells (Figure 3, C and D).
Similar effects were also observed with primary CD4þ
T cells (Figure 3, E and F). METH at 1000 mmol/L
marginally increased the AV (þ) stained SupT1 cells from
1.3% to 3.9% and the primary CD4þ T cells from 5.4% to
7.4%. However, there was minimal change in AV/PI (þ)
and PI (þ) staining. These results suggest that, at physio-
logical concentrations, METH has minimal impact on CD4þ
T-cell apoptosis.
METH Up-Regulates Cellular AntieHIV-1 miRNAs in
CD4þ T Cells
Drugs of abuse, such as cocaine and opioids, have been
demonstrated to target the cellular antieHIV-1 miRNAs to
regulate HIV-1 replication.20,24 Therefore, we examined the
effects of METH on anti-HIV miRNAs in CD4þ T cells. We
used 100 and 500 mmol/L METH for these studies based on
the data on HIV-1 replication. Our real-time PCR analysisThe American Journal of Pathology - ajp.amjpathol.orgrevealed that METH up-regulated expressions of miR-28-
5p, miR-125b, miR-150, and miR-223 in primary CD4þ
T cells (Figure 4A). Notably, the expression of the anti-viral
miR-296-5p was not affected by METH in primary CD4þ T
cells (Figure 4B). Our data also illustrated that, in SupT1
cells, miR-28-5p, miR-125b, and miR-150 expressions were
up-regulated upon METH treatment (Figure 4C). However,
we were unable to amplify miR-223 in SupT1 cells, sug-
gesting that this miRNA may not be expressed in this CD4þ
T-cell model. Notably, expressions of antieHIV-1 miRNAs
(except for miR-150) were higher in cells treated with 500
compared with 100 mmol/L, suggesting a possible correla-
tion between levels of miRNAs and inhibition of HIV-1
replication. METH treatment also up-regulated the expres-
sions of the antieHIV-1 miRNAs in infected primary CD4þ
T cells and SupT1 cells (Supplemental Figure S3A). To
examine whether up-regulation of antieHIV-1 miRNAs can
inhibit HIV-1 replication in CD4þ T cells, we performed
knockdown experiments in SupT1 cells. Because miR-125b
and miR-150 have an overlapping target site on the HIV-1
genome25 (Supplemental Figure S3B), we excluded miR-
150 from our experiments. Furthermore, miR-223 was
also excluded because this miRNA was undetectable in
SupT1 cells (Figure 4B). The miR-125b and miR-28-5p
were knocked down in SupT1 cells by transfecting the
respective anti-miRs and measuring knockdown efﬁciency
by real-time PCR (data not shown). After 24 hours, the cells
with the anti-miR or scrambled controls were then infected
with pseudotyped HIV-1 luciferase reporter virions. Data
presented in Figure 4D illustrated that both antiemiR-125b
and antiemiR-28-5p transfected cells have increased lucif-
erase activity compared with cells with the scrambled
controls. Thus, our data solidiﬁed that miR-125b and95
Figure 3 Effects of METH on HIV-1 LTR-driven transcription and cytotoxicity. A: SupT1 cells and primary CD4þ T cells were transfected with HIV-1 LTR-GFP
reporter construct and treated with METH for 24 hours. HIV-1 LTR-driven GFP expression was measured by FACS and expressed as relative GFP expression. B:
MTT-based cytotoxicity assay using SupT1 and primary CD4þ T cells. Cells were treated with METH, and cytotoxicity was measured by MTT assay after 24 hours.
Cellular apoptosis was measured by AV and PI staining using FACS in SupT1 cells (C and D) and primary CD4þ T cells (E and F) from three different donors.
Results are expressed as means  SD from three independent experiments. Statistical analysis was performed by analysis of variance.
Mantri et almiR-28-5p negatively regulate HIV-1 replication and sug-
gested that METH-induced up-regulation of antieHIV-1
miRNAs may inhibit HIV-1 replication in CD4þ T cells.Discussion
METH use is a major public health concern, with approxi-
mately 35 million users worldwide.26 In the United States,
METH abuse has reached epidemic levels, with an estimated
1.5 million regular users and 11 million reported to use it at
least once in their lifetime.27,28 METH use is particularly
prevalent among HIV-1 patients, with 10% to 15% of HIV-
1epositive individuals acknowledging METH use.29 This
may be due to the fact that METH is the most widely used
recreational drug among men who have sex with men29e31
and is associated with doubling the risk of HIV-1 acquis-
ition.32e36 In addition to men who have sex with men, a
strong correlation between METH use and HIV infection has
been observed among heterosexual men37 and female sex
workers.38 Notably, METH use has also been suggested to
play a role in rapid progression to AIDS and to increase virus
load in the central nervous system of HIV-infected peo-
ple.14,39 However, the molecular mechanisms underlying the
interaction between METH abuse and HIV-1 infection/
replication/disease progression are not clearly understood.
In vitro studies suggest that METH enhances HIV-1
replication in various HIV-1epermissive cells, including
monocyte-derived macrophages and DCs.15,16 METH has96also been shown to increase replication of the feline im-
munodeﬁciency virus in astrocytes.40 Intriguingly, the ef-
fects of METH on HIV-1 replication in human CD4þ
T cells that are the primary targets of HIV-1 infection and
replication in vivo remain largely unclear. Therefore, we
examined the effects of METH on HIV-1 replication using
primary CD4þ T cells isolated from human PBMCs. The
concentration of METH used in our study mimics that of
drug abusers, which can vary from 10 to 50 mmol/L in blood
and from 240 to 1144 mmol/L in spleen and brain.21,22 Our
data revealed that METH at concentrations of 1 to 50
mmol/L had no effect on HIV-1 replication in SupT1 and
primary CD4þ T cells (Supplemental Figure S1). However,
at concentrations of 100 to 1000 mmol/L, METH inhibited
viral replication in a dose-dependent manner in both pri-
mary and model CD4þ T cells (Figure 1). This is in contrast
to the study by Toussi et al18 that showed that METH at
concentrations up to 150 mmol/L enhances HIV-1 replica-
tion in the peripheral CD4þ T cells of JR-CSF/hu-CycT1
HIV-1 transgenic mouse. This double-transgenic mouse is
populated with mouse cells that express the HIV-1 JR-CSF
provirus and produce human cyclin T1 gene, enabling
support of Tat-mediated transactivation of HIV LTR in the
mouse CD4þ T cells and myeloid-lineage cells.41 The
limitations of this model are the following: i) it is not a
humanized mouse model and, therefore, does not use human
CD4þ T cells, ii) the provirus is integrated in every mouse
cell and can be expressed by any cell type that supports
HIV-1 LTR transcription, and iii) the mouse cells cannot beajp.amjpathol.org - The American Journal of Pathology
Figure 4 METH up-regulates antieHIV-1 miRNAs in CD4þ T cells. METH up-regulates antieHIV-1 miRNA expression in primary CD4þ T cells (nZ 6) (A) and
CD4þ T-cell model SupT1 cells (C). Cells were treated with METH for 48 hours, and expression of cellular miRNAs was analyzed by real-time RT-PCR using RNA
isolated from METH-treated cells. miRNA expression levels were determined by miRNA-speciﬁc primers and normalized to 5s-rRNA. B: Expression of miR-296-5p
in primary CD4þ T cells (n Z 3) as a positive control. D: Knockdown experiments were conducted in SupT1 cells using anti-miRs. Anti-miRs or scrambled
control oligos were transfected into SupT1 cells using the Neon Transfection System. These cells were then infected with VSV-Gepseudotyped HIV-1 luciferase
reporter virus. Infection was determined by measuring luciferase activity in the cellular lysates. Luciferase activity was normalized to total protein content of
the lysate. Knockdown of miR-125b and miR-28-5p resulted in increased luciferase activity. Results are expressed as means  SD from three independent
experiments. Statistical analysis was performed by analysis of variance. *P < 0.05.
METH Inhibits HIV-1 Replicationinfected with HIV-1 and, therefore, only examine effects of
METH on HIV-1 LTR-driven transcription. These authors
also described that METH enhances replication of R5 tropic
JR-CSF HIV-1 in human CD4þ T cells. This is in contrast
to our data that showed inhibitory effects of METH on
replication of X4 tropic HIV-1 LAI in CD4þ T cells. HIV-1
infection is mediated by the cellular receptor, CD4, and the
coreceptors, CXCR4 and CCR5.42 X4 virions use CXCR4,
whereas CCR5 is used by R5 tropic virions.42 Because
primary CD4þ T cells express both the CXCR4 and CCR5
coreceptors, they can be infected by both X4 and R5 vi-
rions.42 There is evidence that CD4þ T cells infected with
R5 HIV-1 produce more virions over time than X4 virione
infected CD4þ T cells.23 Therefore, we rationalized that
METH’s effect on HIV-1 replication in CD4þ T cells may
depend on coreceptor requirement for entry. Intriguingly,
the infection experiments with R5 HIV-1 BAL virions also
illustrated that METH inhibits replication of R5 virions inThe American Journal of Pathology - ajp.amjpathol.orgprimary CD4þ T cells (Figure 2). We acknowledge that
intracellular p24 was measured in the R5 infection experi-
ments in contrast to extracellular p24 measurements by
Toussi et al.18 However, it is unlikely that the methods used
can explain the contrasting data given that extracellular p24
level is most likely dependent on intracellular p24 produc-
tion. It is also likely that METH may have differential ef-
fects on the replication kinetics of BAL and JR-CSF virions
in CD4þ T cells. A major difference is that we treated the
cells with METH only once, whereas Toussi et al18 added
METH to the cells every day. Whether this distinct pattern
of METH exposure is responsible for the contrasting data
remains to be elucidated. In addition, the possibility that
metabolites generated under single and long-term METH
exposure may have a differential effect on CD4þ T-cell
function and HIV-1 replication cannot be excluded.
Nevertheless, when the coreceptor requirement or viral entry
was abrogated by VSV-G pseudotyping, METH also97
Mantri et alinhibited single-cycle replication of HIV-1 in CD4þ T cells
(Supplemental Figure S1, A and B). Therefore, it is
reasonable to conclude that METH’s effect on HIV-1
replication may not depend solely on infectivity and/or
coreceptor requirement but also on postentry steps.
HIV-1 postentry steps broadly include reverse transcrip-
tion, integration, transcription, translation, assembly, and
release. Published data suggest that METH may regulate the
entry step of the HIV-1 life cycle. For example, METH has
been shown to induce dendritic cell-speciﬁc intercellular
adhesion molecule-3-grabbing non-integrin to facilitate virus
dissemination43 and decrease the secretion of the chemokines,
such as macrophage inﬂammatory proteins 1a and 1b and
regulated on activation normal T-cell expressed and secreted,
that prevent entry of virus into cells.44 METH has also been
shown to increase CCR5 expression and down-regulate the
expression of anti-viral cytokine, interferon-a.16,45 However,
there is also precedence that METH regulates viral postentry
steps, such as HIV-1 LTR-driven transcription.17,18 There-
fore, we examined the effects of METH on viral transcription
in CD4þ T cells using HIV-1 LTR-based reporter constructs.
Interestingly, METH treatment did not alter HIV-1 LTR-
driven transcription in SupT1 or primary CD4þ T cells
(Figure 3A), implying that the inhibitory effect of METH on
HIV-1 replication was most likely not due to decreased viral
transcription. Furthermore, METH’s inhibitory effect on
HIV-1 replication is most likely not due to induction of
cellular apoptosis because METH did not increase the per-
centage of AV (þ) and/or PI (þ) cells (Figure 3, CeF).
Therefore, we investigated the effects of METH on viral
translation because our earlier report suggested that drugs of
abuse, such as cocaine, regulate HIV-1 protein translation in
CD4þ T cells by down-regulating the antieHIV-1 miRNA
miR-125b.20 In addition, opioids are also shown to target viral
translation by regulating antieHIV-1 miRNAs.24 The real-
time PCR data revealed that METH up-regulates the expres-
sion of antieHIV-1 miRNAs, such as miR-28-5p, miR-125b,
miR-150, and miR-223 in primary CD4þ T cells (Figure 4A).
Knockdown analysis solidiﬁed a role of miR-125b and miR-
28-5p in regulating HIV-1 replication in CD4þ T cells
(Figure 4D). Therefore, we hypothesize that METH inhibits
HIV-1 replication in CD4þ T cells by up-regulating the
cellular antieHIV-miRNAs and inhibiting viral protein
translation. However, further studies are required to establish
a direct link between up-regulation of antieHIV-1 miRNAs
and HIV-1 replication in METH-treated cells.
Accumulating evidence suggests that METH can alter or
suppress functions of immune cells, including CD4þ
T cells. METH has been demonstrated to regulate T-cell
proliferation, cytokine production, oxidative stress, and
mitochondrial function.46,47 However, the mechanisms by
which METH may regulate cellular miRNAs in CD4þ
T cells are not clearly understood. We envision several
pathways that can be targeted by METH to regulate antie
HIV-1 miRNAs in CD4þ T cells. For example, METH is
known to regulate the catecholamine neurotransmitter,98dopamine (DA).48 Notably, DA signaling is known to
regulate expression of cellular miRNAs, such as miR-132
and miR-181a.49,50 Because CD4þ T cells synthesize,
transport, reuptake, and express DA receptors,51 it is plau-
sible that METH may target the DA signaling to regulate the
antieHIV-1 miRNAs. Furthermore, METH may use
epigenetic mechanisms, such as DNA methylation, to
regulate cellular miRNAs. This is because the promoter of
miR-125b contains CpG-rich regions52 and the bioinfor-
matics analyses illustrate that the promoter sequences of
miR-150 also contain CpG islands (data not shown).
Because METH has been known to regulate gene expres-
sion by altering DNA methylation in neuronal cells,53 it is
also possible that METH may up-regulate these miRNAs by
promoter methylation. In addition, METH’s effect on the
biogenesis pathway of cellular miRNAs in CD4þ T cells
cannot be excluded. However, further studies are required to
elucidate the exact mechanism by which METH regulates
cellular miRNAs and exerts an inhibitory effect on HIV-1
replication in CD4þ T cells.
Although epidemiological studies suggest a possible as-
sociation between METH use and HIV-1 disease progres-
sion, a direct link between METH use and HIV-1
replication/disease progression in human patients remains to
be established. There are also inherent difﬁculties associated
with studying drug-abusing HIV-1einfected patients. For
example, history and route of drug use, amount and
formulation of drug used, single or concurrent use of other
drugs, and poor nutrition can also inﬂuence outcomes of
HIV-1 disease. Furthermore, use of METH and other illicit
drugs is often associated with a reduction or nonadherence
to antiretroviral therapy, which severely complicates a direct
correlation between substance use and worsening of HIV-1
disease.54e58 Therefore, the increased pathogenesis in
METH-abusing individuals has been mainly attributed to
nonadherence to antiretroviral therapy. Data presented
herein depict that METH at concentrations (10 to 50 mmol/L)
reported in the blood of METH abusers has no/minimal effect
on HIV-1 replication in CD4þ T cells, implying that METH
abuse may not accentuate viral load in the periphery. This
contention is supported by a study of simian immunodeﬁ-
ciency viruseinfected macaques by Marcondes et al39 illus-
trating that METH administration had no effect on plasma
viral loads. However, these authors reported that METH led
to a signiﬁcantly increased viral load in the brain.39 There-
fore, it is plausible that METH may not affect viral load in the
periphery but can enhance HIV-1 viral load in the brain.
Given that our studies are conducted in the pure cultures of
CD4þ T cells, the in vivo implications of these data may be
limited. Further studies are needed to examine whether
METH confers similar effects on HIV-1 replication in the
mixed cultures of PBMCs. Most importantly, studies with a
humanized mouse model will help us comprehensively
evaluate the molecular effects of METH on HIV-1 replication
and disease progression. Nevertheless, our observations
emphasize the complex interaction between substanceajp.amjpathol.org - The American Journal of Pathology
METH Inhibits HIV-1 Replicationuse and HIV-1 disease and highlight the critical need for
molecular studies to comprehensively evaluate effects of
substance use on HIV-1 infection, replication, and disease
progression.Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2013.09.011.References
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